PreciseDx Company

PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, enabling better and more personalized treatment and outcomes. Clinical teams can rely on PreciseDx for unmatched insights and actionable intelligence in determining the best treatment for each patient. Combining the power of artificial intelligence with its proprietary Morphology Feature Array™, PreciseDx creates disease-specific assays that deliver new levels of pathology information and insight on each patient's risk profile and likely outcomes to aid in treatment decision-making.
Industry: Data processing
Headquarters: New York, New York, United States
Funding Status: Early Stage Venture
Investors Number: 4
Total Funding: 10750000
Last Funding Date: 2022-01-11
Last Funding Type: Series A

Visit Website
Register and Claim Ownership